Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Caredx Inc (CDNA)

Caredx Inc (CDNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,297,960
  • Shares Outstanding, K 53,458
  • Annual Sales, $ 296,400 K
  • Annual Income, $ -30,660 K
  • 60-Month Beta 0.89
  • Price/Sales 4.27
  • Price/Cash Flow N/A
  • Price/Book 2.84
Trade CDNA with:

Options Overview Details

View History
  • Implied Volatility 76.89% ( +5.83%)
  • Historical Volatility 75.73%
  • IV Percentile 38%
  • IV Rank 36.88%
  • IV High 128.43% on 12/20/21
  • IV Low 46.78% on 08/24/21
  • Put/Call Vol Ratio 0.83
  • Today's Volume 11
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 1,536
  • Open Int (30-Day) 1,378

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.39
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.40
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -69.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.52 +4.69%
on 07/18/22
27.33 -17.56%
on 08/08/22
-0.37 (-1.62%)
since 07/15/22
3-Month
19.34 +16.46%
on 06/14/22
27.35 -17.62%
on 06/08/22
-2.39 (-9.59%)
since 05/16/22
52-Week
19.34 +16.46%
on 06/14/22
81.45 -72.34%
on 08/31/21
-48.72 (-68.38%)
since 08/16/21

Most Recent Stories

More News
CareDx and MOTTEP Co-Host Health Equity Summit

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients...

CDNA : 22.53 (-7.21%)
CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates

CareDx (CDNA) delivered earnings and revenue surprises of -62.50% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CDNA : 22.53 (-7.21%)
IDXG : 2.1500 (-13.83%)
CareDx Reports Second Quarter 2022 Results

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients...

CDNA : 22.53 (-7.21%)
CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients...

CDNA : 22.53 (-7.21%)
CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients...

CDNA : 22.53 (-7.21%)
CareDx to Report Second Quarter 2022 Financial Results

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients...

CDNA : 22.53 (-7.21%)
CareDx Demonstrates Industry-Leading Commitment to Advancing Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 2022 American Society of Transplant Surgeons Symposium

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients...

CDNA : 22.53 (-7.21%)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CareDx, Inc. (CDNA)

The Law Offices of Frank R. Cruz reminds investors of the upcoming July 22, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired CareDx, Inc. (“CareDx”...

CDNA : 22.53 (-7.21%)
Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against CareDx, Inc. (CDNA)

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed...

CDNA : 22.53 (-7.21%)
CDNA LAWSUIT ALERT: Levi & Korsinsky Notifies CareDx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) of a class action securities lawsuit. CLASS...

CDNA : 22.53 (-7.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of...

See More

Key Turning Points

3rd Resistance Point 25.89
2nd Resistance Point 25.02
1st Resistance Point 23.78
Last Price 22.53
1st Support Level 21.67
2nd Support Level 20.80
3rd Support Level 19.56

See More

52-Week High 81.45
Fibonacci 61.8% 57.73
Fibonacci 50% 50.40
Fibonacci 38.2% 43.07
Last Price 22.53
52-Week Low 19.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar